Cybin (CYBN) stock earns Guggenheim's Buy rating with a $35 target, as the firm cites blockbuster potential for CYB003 in line with J&J's (JNJ) Spravato. Read more here.

Spravato (esketamine) is prescribed for adults to treat: major depressive disorder (MDD), also called depression, with suicidal thoughts or actions treatment-resistant depression For MDD ...

Analysts do not believe the Phase III stumble for aticaprant will derail J&J’s broader neuroscience strategy, particularly ...

Psychiatry was once big business for pharma, with drugs like Prozac making billions. Now a few breakthroughs are reviving ...

Johnson & Johnson (NYSE:JNJ) decided to discontinue the Phase 3 VENTURA development program evaluating aticaprant, a kappa ...

Up to 40% of people who suffer from depression are unable to find any relief for their condition. But now, Blessing ...

In the ESCAPE-TRD study, Spravato outperformed quetiapine on the main endpoint of achieving remission at eight weeks, measured by the Montgomery-Åsberg Depression Rating Scale (MADRS), with rates ...

Johnson & Johnson’s other depression drug Spravato (esketamine), in January, received FDA approval as the only monotherapy for adults living with major depressive disorder who have had an ...

Johnson & Johnson will stop late-stage studies of its experimental drug to treat major depressive disorder due to a lack of ...

Spravato is the first ketamine-based medicine approved to treat depression, and also the first of a new class of glutamate NMDA receptor-targeting drugs that have ended a decades-long drought at ...

Ketamine advertisements are popping up all around us. With few regulations in place, might we be witnessing another opioid ...